Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion☆
To access this article, please choose from the options below
☆ Financial support for this study was provided by FEI Women's Health (now DuraMed), producers of ParagardÒ T380A intrauterine copper contraceptive, who sponsored a Staff Training Pilot at Planned Parenthood Golden Gate (part of the intervention study). Ms. Hendlish is concurrently a research consultant for Berlex, Inc (now Bayer Health Care, Inc.), producers of Mirena® levonorgestrel-releasing intrauterine system.
PII: S0010-7824(08)00108-X
doi:10.1016/j.contraception.2008.03.003
© 2008 Elsevier Inc. All rights reserved.
